Neoadjuvant treatment of XXXX --Clinical and research perspective.

@entity1 @entity0 @entity3003 @entity10160 @entity1722
Neoadjuvant therapy is very often an adequate alternative to adjuvant therapy. This review is summarizing the recent advances made in the area of neoadjuvant therapy in @entity0 . The focus will lie on recently published clinical trials but will not further highlight surgical, imaging and radiooncological issues related to neoadjuvant therapy. RECENT FINDINGS: Within the last 1-1.5 years it has been discussed if neoadjuvant treatment can be used as faster way to get access to new therapies, based on new data in @entity1722 + @entity0 suggesting a higher pCR rate when a dual anti- @entity1722 therapy was used. Nevertheless this higher pCR rate does not necessarily translate always into a better survival. In TNBC @entity3003 could be identified as an asset for @entity1 , especially in @entity1 with gBRCA mutations. However, mature long term data are still missing. The neoadjuvant approach is ideal to identify new biomarkers which predict response or resistance to the given treatment. Tumour infiltrating lymphocytes and @entity10160 mutations are amongst the most promising markers. SUMMARY: Neoadjuvant treatment should be considered for all @entity1 with @entity1722 -positive or triple negative @entity0 . Clinical trials in this setting are currently investigating new approaches.
